文献速递慢性肾脏病

美国成人中肌肉减少症、肥胖与死亡率在慢性肾脏病与非慢性肾脏病患者中的关系

Sarcopenia, obesity, and mortality in US adults with and without chronic kidney disease.
PubMed 文献 · Kidney Int Rep · 2016-11-04

研究基于1999-2004年美国国家健康与营养调查的成人数据,分析肌肉和脂肪量与全因死亡率的关系在慢性肾脏病(CKD)患者与非CKD患者间是否不同。CKD改变了体成分与死亡率的关联(交互作用P=0.01)。非CKD者中肌肉减少症和肌肉减少性肥胖与死亡率升高独立相关,而CKD者中无此关联;肥胖者死亡风险最低,但合并肌肉减少症者风险升高。

要点

  • CKD显著改变体成分与全因死亡率的关联(交互作用P=0.01)。
  • 非CKD者中肌肉减少症和肌肉减少性肥胖与死亡率升高独立相关。
  • CKD者中肥胖合并肌肉减少症与死亡风险升高相关,但肌肉减少性肥胖无此关联。

核心结论

  • 肌肉减少症与死亡率增加相关且不受eGFR影响,但过多脂肪在CKD患者中改变此关联。
  • 未来关于CKD患者预后及减重和运动干预的研究应同时考虑肌肉量和脂肪量而非孤立评估。

研究设计与样本

  • 研究分析了1999-2004年美国国家健康与营养调查的成人参与者的肌肉和脂肪量异常。
  • 比较了CKD患者与非CKD患者体成分与全因死亡率关联的差异。

主要发现

  • CKD改变了体成分与死亡率的关联(交互作用P=0.01)。
  • 非CKD参与者中,肌肉减少症与正常体成分相比全因死亡率风险比为HR 1.44(95%CI 1.07-1.93),肌肉减少性肥胖为HR 1.64(95%CI 1.26-2.13)。
  • CKD参与者中肌肉减少症和肌肉减少性肥胖与死亡率的关联不存在。
  • 肥胖者调整后死亡风险最低,肥胖合并肌肉减少症者风险升高(HR 1.43,95%CI 1.05-1.95),而肥胖合并肌肉减少性肥胖者与肥胖者相比无显著差异(HR 1.21,95%CI 0.89-1.65;按CKD状态交互作用P=0.003)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In pre-dialysis chronic kidney disease (CKD), the association of muscle mass with mortality is poorly defined, and no study has examined outcomes related to the co-occurrence of low muscle mass and excess adiposity (sarcopenic-obesity). Methods: We examined abnormalities of muscle and fat mass in adult participants of the National Health and Nutrition Examination Survey 1999-2004. We determined whether associations of body composition with all-cause mortality differed between participants with CKD compared to those without. RESULTS: CKD modified the association of body composition with mortality (p=0.01 for interaction). In participants without CKD, both sarcopenia and sarcopenic obesity were independently associated with increased mortality compared with normal body composition (hazard ratio (HR) 1.44 (95%CI 1.07-1.93) and 1.64 (95%CI 1.26-2.13), respectively). These associations were not present among participants with CKD. Conversely, obese persons had the lowest adjusted risk of death, with an increased risk among those with sarcopenia (HR 1.43 (95%CI 1.05-1.95)) but not sarcopenic-obesity (p=0.003 for interaction by CKD status; HR 1.21 (95%CI 0.89-1.65)), compared with obesity. CONCLUSION: Sarcopenia associates with increased mortality regardless of eGFR, but excess adiposity modifies this association among people with CKD. Future studies of prognosis and weight loss and exercise interventions in CKD patients should consider muscle mass and adiposity together rather than in isolation.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Androga L, Sharma D, Amodu A, et al. Sarcopenia, obesity, and mortality in US adults with and without chronic kidney disease. Kidney Int Rep. 2016. PMID: 28439567. doi:10.1016/j.ekir.2016.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。